Diabetic nephropathy: The role of inflammation in fibroblast activation and kidney fibrosis

Frontiers in Endocrinology

Volumn 4, Issue FEB, 2013, Pages

  Kanasaki, Keizo ^a   Taduri, Gangadhar ^b   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokines; Diabetic nephropathies; EMT; EndMT; Fibroblasts; Inflammation; Kidney fibrosis

Indexed keywords

BARDOXOLONE; CD31 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR; SPIRONOLACTONE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; DENDRITIC CELL; DIABETIC NEPHROPATHY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; NONHUMAN; PERICYTE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84880765768     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00007     Document Type: Review

References (192)

1. Abbate, M., Zoja, C., and Remuzzi, G. (2006). How does proteinuria cause progressive renal damage? J. Am. Soc. Nephrol. 17, 2974-2984.
2. Abe, R., Donnelly, S. C., Peng, T., Bucala, R., and Metz, C. N. (2001). Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166, 7556-7562.
3. Adhikary, L., Chow, F., Nikolic-Paterson, D. J., Stambe, C., Dowling, J., Atkins, R. C., and Tesch, G. H. (2004). Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47, 1210-1222.
4. American Diabetes Association. (2011). Standards of medical care in diabetes - 2011. Diabetes Care 34(Suppl. 1), S11-S61.
5. Aresu, L., Rastaldi, M. P., Scanziani, E., Baily, J., Radaelli, E., Pregel, P., et al. (2007). Epithelial-mesenchymal transition (EMT) of renal tubular cells in canine glomerulonephritis. Virchows Arch. 451, 937-942.
6. Bakris, G. L., Weir, M. R., Shanifar, S., Zhang, Z., Douglas, J., van Dijk, D. J., et al. (2003). Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med. 163, 1555-1565.
7. Barnes, J. L., and Gorin, Y. (2011). Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 79, 944-956.
8. Bechtel, W., McGoohan, S., Zeisberg, E. M., Muller, G. A., Kalbacher, H., Salant, D. J., et al. (2010). Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16, 544-550.
9. Boonla, C., Krieglstein, K., Bovornpadungkitti, S., Strutz, F., Spittau, B., Predanon, C., et al. (2011). Fibrosis and evidence for epithelial-mesenchymal transition in the kidneys of patients with staghorn calculi. BJU Int. 108, 1336-1345.
10. Boor, P., and Floege, J. (2011). Chronic kidney disease growth factors in renal fibrosis. Clin. Exp. Pharmacol. Physiol. 38, 441-450.
11. Border, W. A., and Noble, N. A. (1994). Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292.
12. Bottinger, E. P. (2007). TGF-beta in renal injury and disease. Semin. Nephrol. 27, 309-320.
13. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869.
14. Brorsson, C., and Pociot, F. (2011). Genetics of diabetic nephropathy in diverse ethnic groups. Contrib. Nephrol. 170, 8-18.
15. Bullard, K. M., Longaker, M. T., and Lorenz, H. P. (2003). Fetal wound healing: current biology. World J. Surg. 27, 54-61.
16. Chen, Y. T., Chang, F. C., Wu, C. F., Chou, Y. H., Hsu, H. L., Chiang, W. C., et al. (2011). Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 80, 1170-1181.
17. Cheng, H. F., Wang, C. J., Moeckel, G. W., Zhang, M. Z., McKanna, J. A., and Harris, R. C. (2002). Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int. 62, 929-939.
18. Cherney, D. Z., Miller, J. A., Scholey, J. W., Bradley, T. J., Slorach, C., Curtis, J. R., et al. (2008a). The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57, 688-695.
19. Cherney, D. Z., Scholey, J. W., Nasrallah, R., Dekker, M. G., Slorach, C., Bradley, T. J., et al. (2008b). Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am. J. Physiol. Renal Physiol. 294, F1336-F1341.
20. Choi, K., Lee, K., Ryu, S. W., Im, M., Kook, K. H., and Choi, C. (2012). Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol. Vis. 18, 1010-1020.
21. Chow, F., Ozols, E., Nikolic-Paterson, D. J., Atkins, R. C., and Tesch, G. H. (2007a). Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 65, 116-128.
22. Chow, F. Y., Nikolic-Paterson, D. J., Ma, F. Y., Ozols, E., Rollins, B. J., and Tesch, G. H. (2007b). Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50, 471-480.
23. Chow, F. Y., Nikolic-Paterson, D. J., Atkins, R. C., and Tesch, G. H. (2004). Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol. Dial. Transplant. 19, 2987-2996.
24. Chow, F. Y., Nikolic-Paterson, D. J., Ozols, E., Atkins, R. C., and Tesch, G. H. (2005). Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 16, 1711-1722.
25. Chung, A. C., and Lan, H. Y. (2011). Chemokines in renal injury. J. Am. Soc. Nephrol. 22, 802-809.
26. Coca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M., and Parikh, C. R. (2012). Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch. Intern. Med. 172, 761-769.
27. Cravedi, P., Ruggenenti, P., and Remuzzi, G. (2012). Proteinuria should be used as a surrogate in CKD. Nat. Rev. Nephrol. 8, 301-306.
28. dos Santos, G., Kutuzov, M. A., and Ridge, K. M. (2012). The inflammasome in lung diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 303, L627-L633.
29. Duffield, J. S. (2010). Macrophages and immunologic inflammation of the kidney. Semin. Nephrol. 30, 234-254.
30. Ekert, J. E., Murray, L. A., Das, A. M., Sheng, H., Giles-Komar, J., and Rycyzyn, M. A. (2011). Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis Tissue Repair 4, 23.
31. Elmarakby, A. A., and Sullivan, J. C. (2012). Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc. Ther. 30, 49-59.
32. Erkan, E. (2012). Proteinuria and progression of glomerular diseases. Pediatr. Nephrol. doi: 10.1007/s00467-012-23351 [Epub ahead of print].
33. Ferenbach, D., Kluth, D. C., and Hughes, J. (2007). Inflammatory cells in renal injury and repair. Semin. Nephrol. 27, 250-259.
34. Fernández Fernández, B., Elewa, U., Sánchez-Nino, M. D., Rojas-Rivera, J. E., Martin-Cleary, C., Egido, J., et al. (2012). 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med. 103, 219-234.
35. Fioretto, P., and Mauer, M. (2011). Effects of pancreas transplantation on the prevention and reversal of diabetic nephropathy. Contrib. Nephrol. 170, 237-246.
36. Fioretto, P., Mauer, S. M., Bilous, R. W., Goetz, F. C., Sutherland, D. E., and Steffes, M. W. (1993). Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 342, 1193-1196.
37. Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C., and Mauer, M. (1998). Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69-75.
38. Floege, J., Eitner, F., and Alpers, C. E. (2008). A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 19, 12-23.
39. Franchi, L., Munoz-Planillo, R., and Nunez, G. (2012). Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13, 325-332.
40. Fujio, K., Okamura, T., Sumitomo, S., and Yamamoto, K. (2012). Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity. Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2012-202341 [Epub ahead of print].
41. Gaede, P., Lund-Andersen, H., Parving, H. H., and Pedersen, O. (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580-591.
42. Gan, Y., Reilkoff, R., Peng, X., Russell, T., Chen, Q., Mathai, S. K., et al. (2011). Role of semaphorin 7a signaling in transforming growth factor beta1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum. 63, 2484-2494.
43. Goel, G., and Perkins, B. A. (2012). Can improved glycemic control slow renal function decline at all stages of diabetic nephropathy? Semin. Nephrol. 32, 423-431.
44. Grande, M. T., and Lopez-Novoa, J. M. (2009). Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol. 5, 319-328.
45. Gumbiner, B. M. (1992). Epithelial morphogenesis. Cell 69, 385-387.
46. Han, S. Y., Kim, C. H., Kim, H. S., Jee, Y. H., Song, Y. H., Lee, M. H., et al. (2006). Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 17, 1362-1372.
47. Hao, S., Shen, H., Hou, Y., Mars, W. M., and Liu, Y. (2010). tPA is a potent mitogen for renal interstitial fibroblasts: role of beta1 integrin/focal adhesion kinase signaling. Am. J. Pathol. 177, 1164-1175.
48. He, W., Dai, C., Li, Y., Zeng, G., Monga, S. P., and Liu, Y. (2009). Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 765-776.
49. Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., et al. (2011). Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343, d6898.
50. Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., et al. (2008). Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172, 288-298.
51. Hertig, A., Anglicheau, D., Verine, J., Pallet, N., Touzot, M., Ancel, P. Y., et al. (2008). Early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 19, 1584-1591.
52. Herzog, E. L., and Bucala, R. (2010). Fibrocytes in health and disease. Exp. Hematol. 38, 548-556.
53. Hewitson, T. D. (2009). Renal tubulointerstitial fibrosis: common but never simple. Am. J. Physiol. Renal Physiol. 296, F1239-F1244.
54. Heymann, F., Meyer-Schwesinger, C., Hamilton-Williams, E. E., Hammerich, L., Panzer, U., Kaden, S., et al. (2009). Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J. Clin. Invest. 119, 1286-1297.
55. Hills, C. E., and Squires, P. E. (2011). The role of TGF-beta and epithelial-to-mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 22, 131-139.
56. Hiromura, K., Kurosawa, M., Yano, S., and Naruse, T. (1998). Tubulointerstitial mast cell infiltration in glomerulonephritis. Am. J. Kidney Dis. 32, 593-599.
57. Hochheiser, K., Engel, D. R., Hammerich, L., Heymann, F., Knolle, P. A., Panzer, U., et al. (2011a). Kidney dendritic cells become pathogenic during crescentic glomerulonephritis with proteinuria. J. Am. Soc. Nephrol. 22, 306-316.
58. Hochheiser, K., Tittel, A., and Kurts, C. (2011b). Kidney dendritic cells in acute and chronic renal disease. Int. J. Exp. Pathol. 92, 193-201.
59. Holdsworth, S. R., and Summers, S. A. (2008). Role of mast cells in progressive renal diseases. J. Am. Soc. Nephrol. 19, 2254-2261.
60. Hu, K., Lin, L., Tan, X., Yang, J., Bu, G., Mars, W. M., et al. (2008). tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J. Am. Soc. Nephrol. 19, 503-514.
61. Hu, K., Wu, C., Mars, W. M., and Liu, Y. (2007). Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J. Clin. Invest. 117, 3821-3832.
62. Hu, K., Yang, J., Tanaka, S., Gonias, S. L., Mars, W. M., and Liu, Y. (2006). Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J. Biol. Chem. 281, 2120-2127.
63. Huebener, P., and Schwabe, R. F. (2012). Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim. Biophys. Acta. doi: 10.1016/j.bbadis.2012.11.017 [Epub ahead of print].
64. Humphreys, B. D., Lin, S. L., Kobayashi, A., Hudson, T. E., Nowlin, B. T., Bonventre, J. V., et al. (2010). Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97.
65. Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., et al. (2010). Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430.
66. Iwano, M., Plieth, D., Danoff, T. M., Xue, C., Okada, H., and Neilson, E. G. (2002). Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350.
67. John, R., and Nelson, P. J. (2007). Dendritic cells in the kidney. J. Am. Soc. Nephrol. 18, 2628-2635.
68. Kaissling, B., and Le Hir, M. (2008). The renal cortical interstitium: morphological and functional aspects. Histochem. Cell Biol. 130, 247-262.
69. Kalluri, R., and Neilson, E. G. (2003). Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784.
70. Kalluri, R., and Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428.
71. Kanamaru, Y., Scandiuzzi, L., Essig, M., Brochetta, C., Guerin-Marchand, C., Tomino, Y., et al. (2006). Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis. J. Immunol. 176, 5607-5615.
72. Kanasaki, K., Koya, D., Sugimoto, T., Isono, M., Kashiwagi, A., and Haneda, M. (2003). N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J. Am. Soc. Nephrol. 14, 863-872.
73. Kanasaki, M., Nagai, T., Kitada, M., Koya, D., and Kanasaki, K. (2011). Elevation of the anti-fibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair 4, 25.
74. Khan, K. N., Stanfield, K. M., Harris, R. K., and Baron, D. A. (2001). Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail. 23, 321-330.
75. Kim, J. M., Heo, H. S., Choi, Y. J., Ye, B. H., Mi Ha, Y., Seo, A. Y., et al. (2011). Inhibition of NF-kappaB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney. Exp. Gerontol. 46, 542-548.
76. Ko, G. J., Boo, C. S., Jo, S. K., Cho, W. Y., and Kim, H. K. (2008a). Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol. Dial. Transplant. 23, 842-852.
77. Ko, G. J., Kang, Y. S., Han, S. Y., Lee, M. H., Song, H. K., Han, K. H., et al. (2008b). Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. 23, 2750-2760.
78. Komers, R., Lindsley, J. N., Oyama, T. T., and Anderson, S. (2007). Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin. Exp. Pharmacol. Physiol. 34, 36-41.
79. Komers, R., Lindsley, J. N., Oyama, T. T., Schutzer, W. E., Reed, J. F., Mader, S. L., et al. (2001). Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. 107, 889-898.
80. Kure, M., Pezzolesi, M. G., Poznik, G. D., Katavetin, P., Skupien, J., Dunn, J. S., et al. (2011). Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes. Mol. Genet. Metab. 103, 60-65.
81. Lan, H. Y. (2011). Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 7, 1056-1067.
82. Lan, H. Y., and Chung, A. C. (2012). TGF-beta/Smad signaling in kidney disease. Semin. Nephrol. 32, 236-243.
83. LeBleu, V. S., and Kalluri, R. (2011). Blockade of PDGF receptor signaling reduces myofibroblast number and attenuates renal fibrosis. Kidney Int. 80, 1119-1121.
84. LeBleu, V. S., Sugimoto, H., Miller, C. A., Gattone, V. H. II, and Kalluri, R. (2008). Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab. Invest. 88, 284-292.
85. Lee, S. B., and Kalluri, R. (2010). Mechanistic connection between inflammation and fibrosis. Kidney Int. 78(Suppl. 119), S22-S26.
86. Lewis, E. J., Hunsicker, L. G., Bain, R. P., and Rohde, R. D. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462.
87. Li, B., Liu, S., Miao, L., and Cai, L. (2012). Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Exp. Diabetes Res. 2012, 216512.
88. Li, J., Qu, X., and Bertram, J. F. (2009a). Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 175, 1380-1388.
89. Li, Y., Tan, X., Dai, C., Stolz, D. B., Wang, D., and Liu, Y. (2009b). Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 1907-1918.
90. Li, L., Zepeda-Orozco, D., Black, R., and Lin, F. (2010). Autophagy is a component of epithelial cell fate in obstructive uropathy. Am. J. Pathol. 176, 1767-1778.
91. Lim, A. K., Ma, F. Y., Nikolic-Paterson, D. J., Kitching, A. R., Thomas, M. C., and Tesch, G. H. (2010). Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury. Diabetologia 53, 1772-1782.
92. Lim, A. K., and Tesch, G. H. (2012). Inflammation in diabetic nephropathy. Mediators Inflamm. 2012, 146154.
93. Lin, L., Bu, G., Mars, W. M., Reeves, W. B., Tanaka, S., and Hu, K. (2010). tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway. Am. J. Pathol. 177, 1687-1696.
94. Lin, S. L., Castano, A. P., Nowlin, B. T., Lupher, M. L. Jr., and Duffield, J. S. (2009). Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J. Immunol. 183, 6733-6743.
95. Lin, S. L., Kisseleva, T., Brenner, D. A., and Duffield, J. S. (2008). Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617-1627.
96. Liu, Y. (2011). Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 7, 684-696.
97. Liu, Y. (2004). Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15, 1-12.
98. Loots, M. A., Lamme, E. N., Mekkes, J. R., Bos, J. D., and Middelkoop, E. (1999). Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch. Dermatol. Res. 291, 93-99.
99. Macconi, D., Chiabrando, C., Schiarea, S., Aiello, S., Cassis, L., Gagliardini, E., et al. (2009). Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J. Am. Soc. Nephrol. 20, 123-130.
100. Maeda, S. (2008). Genetics of diabetic nephropathy. Ther. Adv. Cardiovasc. Dis. 2, 363-371.
101. Maharjan, A. S., Pilling, D., and Gomer, R. H. (2010). Toll-like receptor 2 agonists inhibit human fibrocyte differentiation. Fibrogenesis Tissue Repair 3, 23.
102. Maleszewska, M., Moonen, J. R., Huijkman, N., van de Sluis, B., Krenning, G., and Harmsen, M. C. (2012). IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology. doi: 10.1016/j.imbio.2012.05.026 [Epub ahead of print].
103. Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., et al. (2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553.
104. Matsunaga, A., Kawamoto, M., Shiraishi, S., Yasuda, T., Kajiyama, S., Kurita, S., et al. (2007). Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur. J. Pharmacol. 554, 12-17.
105. Mehrad, B., Burdick, M. D., and Strieter, R. M. (2009). Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 41, 1708-1718.
106. Meng, X. M., Chung, A. C., and Lan, H. Y. (2013). Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin. Sci. (Lond.) 124, 243-254.
107. Meng, X. M., Huang, X. R., Chung, A. C., Qin, W., Shao, X., Igarashi, P., et al. (2010). Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 21, 1477-1487.
108. Meran, S., and Steadman, R. (2011). Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol. 92, 158-167.
109. Mezzano, S., Droguett, A., Burgos, M. E., Ardiles, L. G., Flores, C. A., Aros, C. A., et al. (2003). Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. Suppl. 86, S64-S70.
110. Miyazawa, S., Hotta, O., Doi, N., Natori, Y., and Nishikawa, K. (2004). Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int. 65, 2228-2237.
111. Miyazono, K. (2000). TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev. 11, 15-22.
112. Murray, L. A., Rubinowitz, A., and Herzog, E. L. (2012). Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr. Opin. Rheumatol. 24, 656-662.
113. Nasrallah, R., Robertson, S. J., and Hebert, R. L. (2009). Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice. Am. J. Nephrol. 30, 346-353.
114. Navarro, J. F., Milena, F. J., Mora, C., Leon, C., Claverie, F., Flores, C., et al. (2005). Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. Suppl. 99, S98-S102.
115. Navarro, J. F., Milena, F. J., Mora, C., Leon, C., and Garcia, J. (2006). Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am. J. Nephrol. 26, 562-570.
116. Navarro, J. F., and Mora, C. (2006). Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorldJournal 6, 908-917.
117. Navarro-Gonzalez, J. F., Jarque, A., Muros, M., Mora, C., and Garcia, J. (2009). Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 20, 165-173.
118. Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros de Fuentes, M., and Garcia-Perez, J. (2011). Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7, 327-340.
119. Niedermeier, M., Reich, B., Rodriguez Gomez, M., Denzel, A., Schmidbauer, K., Gobel, N., et al. (2009). CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc. Natl. Acad. Sci. U.S.A. 106, 17892-17897.
120. Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., et al. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28, 103-117.
121. Ostendorf, T., Eitner, F., and Floege, J. (2012). The PDGF family in renal fibrosis. Pediatr. Nephrol. 27, 1041-1050.
122. Paliege, A., Rosenberger, C., Bondke, A., Sciesielski, L., Shina, A., Heyman, S. N., et al. (2010). Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 77, 312-318.
123. Parving, H. H. (2001). Diabetic nephropathy: prevention and treatment. Kidney Int. 60, 2041-2055.
124. Parving, H. H., Brenner, B. M., McMurray, J. J., de Zeeuw, D., Haffner, S. M., Solomon, S. D., et al. (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213.
125. Peng, X., Mathai, S. K., Murray, L. A., Russell, T., Reilkoff, R., Chen, Q., et al. (2011). Local apoptosis promotes collagen production by monocyte-derived cells in transforming growth factor beta1-induced lung fibrosis. Fibrogenesis Tissue Repair 4, 12.
126. Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336.
127. Phanish, M. K., Winn, S. K., and Dockrell, M. E. (2010). Connective tissue growth factor-(CTGF, CCN2) - a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 114, e83-e92.
128. Pilling, D., Buckley, C. D., Salmon, M., and Gomer, R. H. (2003). Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 171, 5537-5546.
129. Pilling, D., Fan, T., Huang, D., Kaul, B., and Gomer, R. H. (2009). Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 4:e7475. doi: 10.1371/journal.pone.0007475
130. Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., et al. (2007). Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J. Immunol. 179, 4035-4044.
131. Pilling, D., Tucker, N. M., and Gomer, R. H. (2006). Aggregated IgG inhibits the differentiation of human fibrocytes. J. Leukoc. Biol. 79, 1242-1251.
132. Pinzani, M. (2008). Welcome to fibrogenesis and tissue repair. Fibrogenesis Tissue Repair 1, 1.
133. Quilley, J., Santos, M., and Pedraza, P. (2011). Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 300, H2316-H2322.
134. RamachandraRao, S. P., Zhu, Y., Ravasi, T., McGowan, T. A., Toh, I., Dunn, S. R., et al. (2009). Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 20, 1765-1775.
135. Rastaldi, M. P., Ferrario, F., Giardino, L., Dell'Antonio, G., Grillo, C., Grillo, P., et al. (2002). Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int. 62, 137-146.
136. Redd, M. J., Cooper, L., Wood, W., Stramer, B., and Martin, P. (2004). Wound healing and inflammation: embryos reveal the way to perfect repair. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 777-784.
137. Remuzzi, G., Schieppati, A., and Ruggenenti, P. (2002). Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145-1151.
138. Ricardo, S. D., van Goor, H., and Eddy, A. A. (2008). Macrophage diversity in renal injury and repair. J. Clin. Invest. 118, 3522-3530.
139. Rieder, F., Kessler, S. P., West, G. A., Bhilocha, S., de la Motte, C., Sadler, T. M., et al. (2011). Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am. J. Pathol. 179, 2660-2673.
140. Ritz, E., Rychlik, I., Locatelli, F., and Halimi, S. (1999). End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34, 795-808.
141. Rivero, A., Mora, C., Muros, M., Garcia, J., Herrera, H., and Navarro-Gonzalez, J. F. (2009). Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. (Lond.) 116, 479-492.
142. Roufosse, C., Bou-Gharios, G., Prodromidi, E., Alexakis, C., Jeffery, R., Khan, S., et al. (2006). Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J. Am. Soc. Nephrol. 17, 775-782.
143. Sakai, N., Wada, T., Matsushima, K., Bucala, R., Iwai, M., Horiuchi, M., and Kaneko, S. (2008). The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J. Hypertens. 26, 780-790.
144. Sakai, N., Wada, T., Yokoyama, H., Lipp, M., Ueha, S., Matsushima, K., et al. (2006). Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc. Natl. Acad. Sci. U.S.A. 103, 14098-14103.
145. Sakamoto-Ihara, T., Suzuki, Y., Kurusu, A., Yamashita, M., Horikoshi, S., and Tomino, Y. (2007). Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy. Inflamm. Res. 56, 421-427.
146. Scholten, D., Reichart, D., Paik, Y. H., Lindert, J., Bhattacharya, J., Glass, C. K., et al. (2011). Migration of fibrocytes in fibrogenic liver injury. Am. J. Pathol. 179, 189-198.
147. Schrimpf, C., and Duffield, J. S. (2011). Mechanisms of fibrosis: the role of the pericyte. Curr. Opin. Nephrol. Hypertens 20, 297-305.
148. Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A., et al. (2007). Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332.
149. Shao, D. D., Suresh, R., Vakil, V., Gomer, R. H., and Pilling, D. (2008). Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol. 83, 1323-1333.
150. Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., et al. (2011). Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144-1151.
151. Shin, D. H., Park, H. M., Jung, K. A., Choi, H. G., Kim, J. A., Kim, D. D., et al. (2010). The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic. Biol. Med. 48, 1051-1063.
152. Sinsakul, M., Sika, M., Rodby, R., Middleton, J., Shyr, Y., Chen, H., et al. (2007). A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Am. J. Kidney Dis. 50, 946-951.
153. Slinin, Y., Ishani, A., Rector, T., Fitzgerald, P., MacDonald, R., Tacklind, J., et al. (2012). Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am. J. Kidney Dis. 60, 747-769.
154. Strutz, F., and Zeisberg, M. (2006). Renal fibroblasts and myofibroblasts in chronic kidney disease. J. Am. Soc. Nephrol. 17, 2992-2998.
155. Strutz, F., Zeisberg, M., Hemmerlein, B., Sattler, B., Hummel, K., Becker, V., et al. (2000). Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 57, 1521-1538.
156. Sugimoto, H., Grahovac, G., Zeisberg, M., and Kalluri, R. (2007). Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56, 1825-1833.
157. Sugimoto, H., LeBleu, V. S., Bosukonda, D., Keck, P., Taduri, G., Bechtel, W., et al. (2012). Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 18, 396-404.
158. Sugimoto, H., Mundel, T. M., Sund, M., Xie, L., Cosgrove, D., and Kalluri, R. (2006). Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl. Acad. Sci. U.S.A. 103, 7321-7326.
159. Surendran, K., Schiavi, S., and Hruska, K. A. (2005). Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J. Am. Soc. Nephrol. 16, 2373-2384.
160. Takakuta, K., Fujimori, A., Chikanishi, T., Tanokura, A., Iwatsuki, Y., Yamamoto, M., et al. (2010). Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur. J. Pharmacol. 629, 118-124.
161. Tan, X., Li, Y., and Liu, Y. (2006). Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 17, 3382-3393.
162. Tapmeier, T. T., Fearn, A., Brown, K., Chowdhury, P., Sacks, S. H., Sheerin, N. S., et al. (2010). Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 78, 351-362.
163. Teteris, S. A., Engel, D. R., and Kurts, C. (2011). Homeostatic and pathogenic role of renal dendritic cells. Kidney Int. 80, 139-145.
164. The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
165. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454.
166. Thomas, R. (2010). The balancing act of autoimmunity: central and peripheral tolerance versus infection control. Int. Rev. Immunol. 29, 211-233.
167. Timoshanko, J. R., Kitching, A. R., Semple, T. J., Tipping, P. G., and Holdsworth, S. R. (2006). A pathogenetic role for mast cells in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 17, 150-159.
168. Togawa, H., Nakanishi, K., Mukaiyama, H., Hama, T., Shima, Y., Sako, M., et al. (2011). Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease. Am. J. Physiol. Renal Physiol. 300, F511-F520.
169. Tu, Y., Jia, R., Ding, G., and Chen, L. (2010). Effect of atorvastatin on dendritic cells of tubulointerstitium in diabetic rats. BMB Rep. 43, 188-192.
170. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865.
171. Usui, H. K., Shikata, K., Sasaki, M., Okada, S., Matsuda, M., Shikata, Y., et al. (2007). Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 56, 363-372.
172. Vernon, M. A., Mylonas, K. J., and Hughes, J. (2010). Macrophages and renal fibrosis. Semin. Nephrol. 30, 302-317.
173. Viswanathan, V. (1999). Type 2 diabetes and diabetic nephropathy in India - magnitude of the problem. Nephrol. Dial. Transplant. 14, 2805-2807.
174. Wada, J., and Makino, H. (2013). Inflammation and the pathogenesis of diabetic nephropathy. Clin. Sci. (Lond.) 124, 139-152.
175. Wada, T., Sakai, N., Sakai, Y., Matsushima, K., Kaneko, S., and Furuichi, K. (2011). Involvement of bone-marrow-derived cells in kidney fibrosis. Clin. Exp. Nephrol. 15, 8-13.
176. Wang, Y., Cao, Q., Zheng, G., Lee, V. W., Zheng, D., Li, X., et al. (2008). By homing to the kidney, activated macrophages potently exacerbate renal injury. Am. J. Pathol. 172, 1491-1499.
177. Wang, Y., and Harris, D. C. (2011). Macrophages in renal disease. J. Am. Soc. Nephrol. 22, 21-27.
178. Wolf, G., and Ritz, E. (2003). Diabetic nephropathy in type 2 diabetes prevention and patient management. J. Am. Soc. Nephrol. 14, 1396-1405.
179. Wynn, T. A. (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117, 524-529.
180. Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210.
181. Wynn, T. A. (2011). Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339-1350.
182. Xu, C., Zhao, J., Loo, W. T., Hao, L., Wang, M., Cheung, M. N., et al. (2012a). Correlation of epigenetic change and identification of risk factors for oral submucous fibrosis. Int. J. Biol. Markers 27, e314-e321.
183. Xu, L., Kanasaki, K., Kitada, M., and Koya, D. (2012b). Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair 5, 13.
184. Yamashita, S., Maeshima, A., and Nojima, Y. (2005). Involvement of renal progenitor tubular cells in epithelial-to-mesenchymal transition in fibrotic rat kidneys. J. Am. Soc. Nephrol. 16, 2044-2051.
185. Yang, J., and Liu, Y. (2002). Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J. Am. Soc. Nephrol. 13, 96-107.
186. Yang, J., Shultz, R. W., Mars, W. M., Wegner, R. E., Li, Y., Dai, C., et al. (2002). Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J. Clin. Invest. 110, 1525-1538.
187. Yeaman, C., Grindstaff, K. K., Hansen, M. D., and Nelson, W. J. (1999). Cell polarity: versatile scaffolds keep things in place. Curr. Biol. 9, R515-R517.
188. Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M., and Kalluri, R. (2008). Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287.
189. Zeisberg, M., and Duffield, J. S. (2010). Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 21, 1247-1253.
190. Zeisberg, M., Hanai, J., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F., et al. (2003). BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968.
191. Zhang, D. D. (2013). Bardoxolone brings Nrf2-based therapies to light. Antioxid. Redox Signal. doi: 10.1089/ars.2012.5118 [Epub ahead of print].
192. Zhou, Y., Mao, H., Li, S., Cao, S., Li, Z., Zhuang, S., et al. (2010). HSP72 inhibits Smad3 activation and nuclear translocation in renal epithelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 21, 598-609.